2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.83
“SELECTIVE ESTROGEN RECEPTOR MODULATOR, OSU-ERB-12, AMELIORATES PRECLINICAL MODELS OF HEPATIC FIBROSIS AND NASH.” Ohio State University
No.82
“PRECLINICAL DEVELOPMENT OF SMALL MOLECULE DRUG DISCOVERY LEADS WITH NOVEL MOAS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH)” Twoxar
No.81
“IRON LOSS TRIGGERS MITOPHAGY THROUGH INDUCTION OF MITOCHONDRIAL FERRITIN” Kawasaki Medicel School
No.80
“Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma” Kawasaki Medical School
No.79
“GPNMB modulates hepatic steatogenesis and liver cancer” Heidelberg University
No.78
“2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity” Kawasaki Medical School
No.77
“Novel autophagy inducer, a4368 improves non-alchoholic steatohepatitis in mice” Autophagy Sciences.
No.76
“Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis” OncoArendi Therapeutics SA.
No.75
“A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers” Future Medicine Co., Ltd.
No.74
"NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID MEDIATORS, PRIMARY METABOLITES AND MICROBIOME IN A STAM MOUSE MODEL, AND THERAPEUTIC POTENTIAL OF A JAPANESE TRADITIONAL MEDICINE, DAISAIKOTO” TSUMURA & Co.